© 2022 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
January 26, 2022
Tebentafusp is now the first FDA-approved therapy to treat unresectable or metastatic uveal melanoma.
January 19, 2022
Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.
January 17, 2022
An expert from The University of Texas MD Anderson Cancer Center offers advice on the best diet to enrich a patient’s microbiome and consequent immunotherapy response.
January 13, 2022
An expert from The University of Texas MD Anderson Cancer Center highlights findings demonstrating the impact that diet and probiotics have in immunotherapy responses.
January 11, 2022
New data support increased fiber consumption and decreased probiotic use among patients receiving immunotherapy.
January 06, 2022
A novel regimen of relatlimab, an LAG-3 inhibitor, plus nivolumab doubled progression-free survival in patients with untreated, advanced melanoma.
December 30, 2021
Patients with various solid tumor types experienced improved antitumor immunity after adhering to a diet with severe caloric restrictions.
December 06, 2021
Pembrolizumab has been approved for the adjuvant treatment of adults and pediatric patients with stage IIB or IIC melanoma who have underwent complete resection.
November 19, 2021
Patients receiving immune checkpoint inhibitors for renal cell carcinoma or melanoma responded well to the COVID-19 vaccine.
November 08, 2021
After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.